73 results about "AntiInfective Drugs" patented technology

Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

This invention relates to an anti-infective compound, more specifically, 6-fluoro-1-methyl-4-oxo-7-(1-piperazine)-4H-[1, 3] thiazine [3, 2-a] quinoline-3-carboxylic mesylate (compound I), its preparation method and its application. Compound I is prepared by reaction of 6-fluoro-1-methyl-4-oxo-7-(1-piperazine)-4H-[1,3]thiazine[3,2-a]quinoline-3-carboxylic acid and methyl sulfonic acid. Compound I can be used as effective component and mixed with normal pharmaceutical carrier to manufacture anti-infective drug composition, which can be tablets, capsules, granules, injection, eye preparations, ear preparations, gynecological preparations, and external use preparations. Compound I has stable properties, and can be easily dissolved in water, thus can be easily manufactured into various preparations used in clinical treatment. The method has such advantages as simple and reasonable process.

The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug for treating various skin infections, such as fungal, bacterial, and / or viral skin infections. The formulation can include anti-infective drug, solvent vehicle, and solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained periods of time. The non-volatile solvent system can also act to plasticize the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

The invention discloses a method for preparing cefixime dispersible tablets, relates to the field of pharmaceutical preparation and particularly relates to cefixime dispersible tablets which are anti-infective agents and the method for preparing the cefixime dispersible tablets. Cefixime serves as an active pharmaceutical ingredient of the cefixime dispersible tablets and auxiliary materials are added in the cefixime dispersible tablets. The auxiliary materials include solubilizing agents, filling agents, lubricating agents, bonding agents and disintegrating agents. The cefixime dispersible tablets include, by weight, 15%-60% of the micronized cefixime, 10%-70% of the filling agents or diluents, 1%-20% of the disintegrating agents, 0.3%-5% of the lubricating agents, 0.5%-10% of the bonding agents and 0.5%-5% of the solubilizing agents, wherein grain diameters of the micronized cefixime range from 20 mu m to 120 mu m. The method has the advantages that the dissolving speed of the cefixime dispersible tablets is rapid and the dissolving is complete.

The invention relates to a 3-aryl-4-(2-glycosyl / amino ethyoxyl)-2(5H)-furanone compound. The 3-aryl-4-(2-glycosyl / amino ethyoxyl)-2(5H)-furanone compound has a structural general formula shown as the specifications. The 3-aryl-4-(2-glycosyl / amino ethyoxyl)-2(5H)-furanone compound has good inhibition effect on staphylococcus epidermidis, Klebsiella pneumonia, novel cryptococcus gattii and the likeand can be used for preparing anti-infective medicaments for treating pneumonia, wound suppuration and the like. The invention discloses a preparation method of the 3-aryl-4-(2-glycosyl / amino ethyoxyl)-2(5H)-furanone compound.

The invention discloses 3-aryl-4-arylamino-2 (5(i)H( / i))-furanone compounds, which are characterized in that the compounds have the following structural general formulas: in formula I, if R1=R3=Br, Cl or OCH3 and R2=R4=R5=R6=R8=H, R7=NO2, F, Cl, Br, OCH3 or OH; if R2=F, Cl, Br, OH, NO2 or OCH3 and R1=R3=R4=R5=R6=R8=H, R7=NO2, F, Cl, Br, OCH3 or OH; if R1=R3=Br, Cl or OCH3 and R2=R4=R5=R6=R8=H, R6=NO2, F, Cl, Br, OCH3 or OH; if R2=F, Cl, Br, OH, NO2 or OCH3 and R1=R3=R4=R5=R8=H, R6=R7=OCH3 or OH; and R1=R3=Br, Cl or OCH3 and R2=R4=R5=R8=H, R6=R7=OCH3 or OH. The compounds of the invention have preferable inhibition effects on staphylococcus epidermidis, Klebsiella pneumoniae, Cryptococcus neoformans and the like, and can be used for preparing anti-infective drugs for treating pneumonia, septic wounds and the like. The invention discloses a preparation method of the compounds.

The present invention belongs to the field of medicine technology and discloses an effective dose containing acetylcysteine or pharmaceutically acceptable salts thereof, and at least one pharmaceutical composition of anti-infective drugs as well as usage and method for making same, wherein the antiinfective drugs are one or several compounds selected from new houttuynine sodium bisulfite or pharmaceutically acceptable salt thereof and / or 14-dehydroxyl-11, 12-dehydro andrographolide-3, 19-di-succinic acid half-ester salts and / or matrine. Said pharmaceutical composition can be made into pharmaceutically acceptable dosage forms and exhibits cooperative building action when being used for diseases such as pneumonia, bronchial asthma, haggis acute inflammation accompanying with chronic emphraxis haggis diseases caused by sensitive bacteria; in addition, possesses excellent stability, exhibits considerably improved effects relative to used individually medicament of the same dose, and results in effects beyond thoughts, possesses wide-ranging applications foreground.

The invention discloses a berberine hydrochloride and fumaric acid eutectic substance as well as a preparation method, composition and an application thereof, specifically discloses a novel berberinehydrochloride and fumaric acid eutectic substance with berberine hydrochloride as an active pharmaceutical ingredient and fumaric acid as a eutectic precursor, a preparation method of the berberine hydrochloride and fumaric acid eutectic substance as well as an application of the berberine hydrochloride and fumaric acid eutectic substance as the active pharmaceutical ingredient in preparation of drugs for preventing and treating cardiovascular diseases, resisting viruses and cancer, reducing blood fat and blood sugar and resisting inflammation, bacteria and infection.

The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.

The invention provides a protective repair hydrogel for damaged parts of skin and mucous membranes. The protective repair hydrogel comprises the following components in percentages by weight: 0.5% to10% of a polymer matrix, 0.001% to 0.1% of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 0.001% to 0.1% of N-hydroxysuccinimide, 0.001% to 0.1% of 5'-hydroxydopamine, 0.01% to 5% of a drug for promoting tissue repair, 0.5% to 5% of an anti-infective drug and 80% to 98% of threefold-distilled water. The invention also provides a preparation method of the protective repair hydrogel for damaged parts of skin and mucous membranes, the weight percentages of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and 5'-hydroxydopamine are optimized, and a layer of protective film can be formed by oxidative crosslinking when the surface of a wound is covered with the protective repair hydrogel, so that the failure of the drug for promoting tissue repair and the anti-infective drug is avoided, and the repair of the wound by the tissue repair drug and the anti-infective drug is also facilitated.

The invention relates to a piperazine urea pleuromutilin derivative and application thereof, belonging to the technical field of antibacterial drugs. The technical problem to be solved by the invention is to provide the piperazine urea pleuromutilin derivative with good antibacterial activity. The structural formula of the piperazine urea pleuromutilin derivative is shown as a formula I in the specification. The piperazine urea pleuromutilin derivative disclosed by the invention is novel in structure and has excellent antibacterial activity. An in-vitro antibacterial experiment obviously showsthat the piperazine urea pleuromutilin derivative has an excellent antibacterial effect on standard drug-resistant staphylococcus aureus strains ATCC33591 and ATCC43300, and on escherichia coli strains ATCC25922 and ATCC25923, is expected to be applied to treatment of bacterial infection caused by staphylococcus aureus and escherichia coli, and provides a new choice for anti-infective drugs.

The invention relates to a rana nigromaculata antimicrobial peptide as well as a gene and application thereof, and belongs to the technical field of biomedicine. The rana nigromaculata antimicrobial peptide is a gene coded single-chain polypeptide separated from an amphibian rana nigromaculata of China, wherein the molecular weight is 1,647.02 Daltons, and the isoelectric point is 11.05; and the complete sequence of the rana nigromaculata antimicrobial peptide is phenylalanine-isoleucine-proline-leucine-valine-serine-glycine-leucine-phenylalanine-serine-arginine-leucine-leucine-glycine-lysine. The coded gene of the rana nigromaculata antimicrobial peptide consists of 316 nucleotides, wherein the mature coded part of the coded gene contains 142nd-186th nucleotides. The artificially synthesized rana nigromaculata antimicrobial peptide has a strong antibacterial effect, has the advantages of high safety, simple sequence and convenience in synthesis, and can be used as a novel anti-infective agent for application.

The invention relates to the antibody engineering and anti-virus medicine fields, and relates to a method for rapid and effective determination of the anti-virus function of recombined human anti-hepatitis B virus antibody. According to the method, settleable virus compound technology is used for establishing a new method for detection and evaluation of anti-virus capability of a molecule. According to the method, the anti-virus and anti-infection capability of the molecule is detected by detection of settleable pathogen compound generation capability of the molecule to be detected, wherein the settleable pathogene compound generation capability of the molecule to be detected is induced in blood serum, and pathogen is virus. The method is used for rapid determination of virus removal and virus infection control capability of an antibody and other anti-infection medicines. The method has the advantages of simple operation process and good result repeatability and is a supplement to the prior art detection and evaluation methods of functions of the anti-virus medicines, and the establishment of the method provides a new choice for research and development of medicines currently having no effective cell and animal infection model virus. The invention also relates to a detection reagent of anti-virus-infection activity, the settleable pathogene compound generated in a detection process and the application of the detection method.

The invention belongs to the field of medical technology, in particular to a guanidyl substitutional tetracycline derivative shown by a general formula (I), wherein R2, R2', R3, R4, R4', R5, R6, R6', R7, R8, R9, r9', R10, R11 and R12 are defined in an instruction book; the invention further relates to a preparation method of compounds, and medicine composites containing the compounds and the application of the compounds to treating and / or preventing tetracyclines sensitive diseases, particular for the application of anti-infective drugs.

The invention discloses a berberine hydrochloride and ibuprofen eutectic substance as well as a preparation method, composition and an application thereof, specifically discloses a novel berberine hydrochloride and ibuprofen eutectic with berberine hydrochloride as an active pharmaceutical ingredient and ibuprofen as a eutectic precursor, a preparation method of the berberine hydrochloride and ibuprofen eutectic as well as an application of the berberine hydrochloride and ibuprofen eutectic as the active pharmaceutical ingredient in preparation of drugs for preventing and treating cardiovascular diseases, resisting viruses and cancer, reducing blood fat and blood sugar and resisting inflammation, bacteria and infection.

The invention discloses a didemethylated actinomycin derivative and an application thereof in preparation of drugs for resisting drug-resistant bacteria infection. The structural formula of the actinomycin double-demethylation derivative Didemactinomycin D is as shown in a formula (I), and the structural formula of the Didemactinomycin X2 is as shown in a formula (II). The actinomycin demethylation derivatives Didemactinomycin D and Didemactinomycin X2 having drug-resistant staphylococcus aureus resistance are separated from a transmethylase inactivated mutant strain ZS0073 / delta acnM of a marine-derived actinomycin D production strain S.costaricaus SCSIO ZS0073. The test results show that the Didemactinomycin D has good inhibitory activity (MIC is 4-32 [mu] g / mL) on 14 strains of staphylococcus aureus, compared with actinomycin D, the toxicity to normal human cells is greatly weakened, and the Didemactinomycin D has important value in development of anti-infective drugs.

The invention discloses blunt snout bream beta-defensin gene, which has a nucleotide sequence represented by SEQ ID NO:1. The invention further discloses recombinant protein encoded by the blunt snout bream beta-defensin gene, and a preparation method thereof, wherein the recombinant protein has an amino acid sequence represented by SEQ ID NO:2. The blunt snout bream beta-defensin recombinant protein provides good bacterial inhibition activities for staphylococcus aureus, streptococcus, ampicillin resistance type escherichia coli, aeromonas hydrophila and the like, and provides a class of new drugs with good therapeutic effects for anti-infective drugs and drug-resistant bacteria. The preparation method for the blunt snout bream beta-defensin recombinant protein has the following advantages that: high purity products can be easily obtained; and compared to the existing chemical synthesis method, the method of the present invention has characteristics of good activity, cost reduction, preparation time shortening, and easy industrial production achievement.

The present invention was made in view of problems relating to stability, reproducibility, economics, and ease of operation in monocyte- or dendritic cell-mediated infectious microorganism research and provides a method for the maintenance culture of monocyte- or dendritic cell-mediated infectious microorganisms using monocytes having proliferative capacity. The present invention is based on the discovery that the dengue virus can infect and proliferate efficiently in human monocytic cells capable of proliferation obtained by introducing a gene into CD14-positive cells and cells (for example,dendritic cells) having phagocytic capacity obtained by inducing differentiation of the monocytic cells. Thereby provided is a novel method for evaluating pharmaceuticals such as compounds and vaccines for the treatment of monocyte- or dendritic cell-mediated infectious microbial infections.

The invention relates to a 3D printing titanium interbody fusion cage as well as a preparation method and an application thereof. The 3D printing titanium interbody fusion cage comprises a Ti6Al4V main body structure and a medicine coating coated on the surface of the main body structure, and the medicine coating comprises a biodegradable high polymer material and an anti-infective drug. Accordingto the 3D printing titanium interbody fusion cage disclosed by the invention, the surface of the main body structure made of a Ti6Al4V material is creatively coated with the medicine coating containing the biodegradable high polymer material and the anti-infective drug, the interbody fusion cage is good in biocompatibility, local postoperative infection can be well prevented by locally releasingthe medicine after the interbody fusion cage is implanted into a focus part, the postoperative infection occurrence rate is greatly reduced, and interbody fusion is assisted.

The invention belongs to the technical field of medicine, and particularly relates to application of hypoxanthine nucleotide in preparation of anti-infective drugs. Experiments prove that the hypoxanthine nucleotide can significantly improve the sensitivity of Escherichia coli, Klebsiella pneumoniae, staphylococcus aureus multi-drug-resistant bacteria, pseudomonas aeruginosa and other bacteria toamoxicillin, cefoperazone, meropenem, gentamicin and other antibiotics, so that the hypoxanthine nucleotide can be used as an anti-infective drug together with antibiotics. Bacteria are killed under the condition of low-concentration antibiotics, a good anti-infection effect is achieved, and meanwhile bacterial drug resistance is reduced.

An oxazolidinone-alkyl amine group-furanone type compound has the flowing general molecular formula. The compound has the better inhibiting effect on staphylococcus epidermidis, klebsiella pneumoniae, cryptococcus neoformans and the like, and can be used for preparing anti-infective drugs for treating intestinal infection, pneumonia, wound suppuration and the like. The invention discloses a preparation method of the compound.

The invention discloses a halogenated furanone compound and the application thereof in preparing anti-infective drugs. The structural formula of the halogenated furanone compound is indicated by the formula (I), II), (III), (IV), (V), (VI), (VII) or (VIII). The halogenated furanone compound designed and synthesized by the invention has good effect in inhibiting the formation of bacterial biomembranes, can be used as a bacterial biomembrane inhibitor, is separately used or used together with antibiotic drug to overcome the problem of clinical antibiotic resistance.

The invention relates to the technical field of polymer synthesis and in particular relates to a specific inhibition compound of an SAHN enzyme protein and a synthetic method of the specific inhibition compound. The specific inhibition compound of escherichia coli SAHN enzyme protein is obtained in a targeted manner by virtue of an organic synthetic method, so that a novel anti-infective drug pilot compound is developed.

The invention provides a drug coating composition for ureteral stents and its preparation method and application; the drug coating composition comprises the following components in parts by weight: 0.3-1.3 parts of rapamycin, puerarin 0.02-0.09 parts, 0.01-0.05 parts of formoterol, 0.2-1.5 parts of anti-infective drugs, 2-6 parts of natural products, 1-2 parts of hydrophilic polymers, 1.3-4.5 parts of additives, 20-90 parts of solvents; The drug coating composition provided by the present invention not only has a good effect of dilating the ureter, but also has antibacterial and anti-inflammatory properties, and can treat ureteral injury through the reasonable combination of the three components of rapamycin, puerarin and anti-infective drugs. At the same time, through the adjustment of hydrophilic polymers and additives, the composition has a long-acting sustained-release effect and achieves a more durable curative effect. It also provides a new strategy for the research and development of new drugs and has a good application prospect.

The invention provides an anti-infective drug, the structure of which is shown as a formula I. The anti-infective drug provided by the invention comprises a stereoisomer, a hydrate, a deuterated substance, an ester, a solvate, a crystal form, a metabolite, and a pharmaceutically acceptable salt or a prodrug, and has stronger bacterial activity and a wider antibacterial spectrum so as to treat infectious diseases.

The invention relates to a new application of exosome secreted by cells, and relates to a preparation method of the exosome and an application of the exosome to treatment of infectious related diseases after being wrapped with antibacterial drugs. Compared with the prior art, the exosome is used as an antibacterial drug carrier, so that the biological effect of the antibacterial drug can be improved, and the effect of the antibacterial drug in the aspect of treating refractory infectious related diseases is enhanced.

Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.

The invention discloses an antibacterial peptide LJ-2 and an application thereof. The amino acid sequence of the antibacterial peptide LJ-2 is as follows: the amino acid sequence of the antibacterialpeptide LJ-2 is shown in the specification: arginine, arginine, valine, leucine, arginine, isoleucine, leucine, lysine, histidine, histidine, glutamine, glycine, leucine, isoleucine, arginine, asparagine, leucine and leucine; the antibacterial peptide LJ-2 has good antibacterial activity on gram-positive bacteria, gram-negative bacteria and fungi, and has the advantages of low hemolysis, heat resistance, salt resistance, acid and alkali resistance and repeated freeze thawing resistance. Therefore, the antibacterial peptide LJ-2 disclosed by the invention has a wide application prospect in thefields of anti-infective drug preparation, animal husbandry development, human disease prevention and treatment, food preservation, detergents, cosmetics and the like.